Warfarin pharmacokinetics

Warfarin pharmacokinetics refers to the complex biological processes governing the absorption, distribution, metabolism, and excretion of the anticoagulant drug warfarin [3, 15]. As a racemic mixture, warfarin's enantiomers are metabolized by different hepatic enzymes; the more potent S-warfarin is primarily processed by Cytochrome P450 2C9 (CYP2C9), while the R-enantiomer is metabolized by CYP3A4, CYP1A2, and CYP2C19 [3, 13]. This pharmacokinetic pathway is a cornerstone of pharmacogenetics, as genetic variations in CYP2C9, along with the pharmacodynamic target Vitamin K epoxide reductase complex subunit 1 (VKORC1), significantly influence individual dose requirements and the risk of adverse events [1, 5, 7]. Clinical management is challenging due to warfarin's narrow therapeutic index, requiring frequent monitoring of the International Normalized Ratio (INR) to prevent life-threatening bleeding or therapeutic failure [15, 16]. Additionally, other proteins such as CYP4F2 and the ABCB1 transporter contribute to the variability in drug response and elimination [2, 3, 8]. Understanding these interactions is vital for managing the high inter-individual variability and numerous drug-drug interactions associated with warfarin therapy [11, 12].

Other names

Warfarin metabolismWarfarin ADMEWarfarin PK pathway

Warfarin acts by inhibiting the Vitamin K epoxide reductase complex subunit 1 (VKORC1), thereby depleting reduced vitamin K and preventing the gamma-carboxylation of clotting factors II, VII, IX, and X [7, 9, 17]. The pharmacokinetic component involves the oxidative metabolism of warfarin enantiomers by various Cytochrome P450 enzymes, primarily CYP2C9 for the S-isomer [3, 13].